Pompano Beach, Fla., July 14, 2014 (GLOBE NEWSWIRE) — DS Healthcare Group, Inc. (DSKX), a leading developer of personal care products and specialty pharmaceuticals, announced today that the first DS Laboratories store worldwide has opened in Shanghai, China in partnership with the Company’s Chinese distributor. The store exclusively features a complete line of DS Healthcare products including the Company’s clinically proven, industry-leading Spectral line of hair loss treatments and Revita hair stimulating shampoos and conditioners. The Company plans to open additional partnership stores worldwide in the coming months.

According to Euromonitor International, total sales of beauty and personal care products in China tripled in size from 2000 to reach an estimated $24 billion in 2010. Euromonitor projects the market will grow to $34 billion by 2015. Analysts credit China’s fast growing middle class for the rapid growth in sales.

“As we build the premier global brand in clinically proven personal care and Rx products, this retail store in Shanghai is an important component of our country-wide distribution and brand building strategy in China. We entered into a distribution agreement with our Chinese partner in September and it’s quickly become a very productive working relationship, as evidenced by the launch of this first DS Laboratories retail boutique. We are excited about the growth potential in this very important global market,” stated DS Healthcare President and CEO Daniel Khesin.

About DS Healthcare Group

DS Healthcare Group Inc. leads in the development of biotechnology for topical therapies. It markets through online and specialty retailers, distributors, cosmetics wholesalers, and salons. Its research has led to a highly innovative portfolio of personal care products and additional innovations in pharmaceutical projects. For more information on DS Healthcare Group’s flagship brand, visit www.dslaboratories.com

ROCKVILLE, Md.–(BUSINESS WIRE)–

Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced an update in its Phase I multi-center dose-escalation study to evaluate the safety, tolerability, dose-limiting toxicities and maximum tolerated dose (MTD) of Supinoxin™ (RX-5902) in cancer patients with solid tumors.

Enrollment into four dose groups has been completed (25, 50, 100 and 150 mg) and no drug related adverse events have been reported. The fifth dose group (225 mg) is ongoing. The maximum tolerated dose of Supinoxin has not yet been achieved. Pharmacokinetic analysis has shown that Supinoxin displays dose-proportional exposure and an estimated oral bioavailability of 51%.

“With the fourth dosing group now complete, we continue to be encouraged by the pharmacokinetics and safety of Supinoxin in patients who have received multiple cycles of treatment. We are on schedule to complete enrollment of patients in this clinical trial by the end of 2014,” stated Rexahn’s Chief Executive Officer, Peter D. Suzdak, Ph.D. “We look forward to the data from this trial, which will further guide the clinical development of this compound.”

The Phase I trial of Supinoxin, which was initiated in August 2013, is a dose-escalation study designed to evaluate the safety, tolerability, dose-limiting toxicities and MTD in patients with solid cancer tumors that have previously failed treatment with approved therapies and shown progression of disease. Secondary endpoints include pharmacokinetic analysis and evaluating the preliminary anti-tumor effects of Supinoxin. This trial is being conducted in three clinical oncology centers in the United States. Each patient has the ability to continue on the drug up to six cycles of treatment (a dosing cycle is defined as 3 weeks of drug treatment followed by 1 week off) if no disease progression is seen. Patients are assessed by CT or MRI prior to the start of therapy and after every two cycles of therapy to assess tumor progression. The trial is using an accelerated dose-escalation design: one patient is treated per dose cycle until a grade 2 related adverse event occurs then three patients will be treated per dose cycle. The decision to escalate dose is made by the data monitoring safety board (DMSB) after completion of one cycle of treatment based on safety and tolerability. Patients have the possibility to receive up to 6 cycles of treatment if the disease does not progress. Tumor biopsy samples are taken to assess the biomarker phospho-P68.

WILMINGTON, Mass., July 17, 2014 /PRNewswire/ — Implant Sciences Corporation (IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today stated that it has shipped over $550,000 in previously unannounced orders of QS-H150 and QS-B220s to multiple customers in North America, Europe, Middle East, and Africa. Customers for the handheld and desktop explosives trace detectors include a major international logistics corporation, a construction company, an airport, and the embassy of a foreign nation. The systems will be used for building security and for the screening of air cargo, and airline passengers and baggage.

“The regulatory certifications we have received so far for our products have established a strong foothold for the Company in aviation security. Adding cargo, passenger, and baggage screening to our existing markets like building security, subways, and critical infrastructure has been an important part of our ability to significantly increase orders received as compared to the the previous year. We anticipate that success in the approval efforts we have underway at the moment will strongly accelerate this trend,” stated Implant Sciences’ Vice President of Sales and Marketing, Dr. Darryl Jones.

About the QS-H150 Handheld Explosives Trace Detector

The QS-H150 utilizes Ion Mobility Spectrometry (IMS) technology, providing fast, accurate detection of trace amounts of a wide variety of military, commercial, and homemade explosives. Built with no radioactive materials and featuring a low-maintenance, self-calibrating, and self-clearing design, the QS-H150 provides very high levels of operational availability. The QS-H150 has been proven to perform well in a wide variety of temperatures and challenging environments, from humid jungles to dry, sand swept deserts.

VIENNA, Va.–(BUSINESS WIRE)–

CEL-SCI Corporation (NYSE MKT:CVM) today announced that Sri Lanka’s Ministry of Health has cleared the Company to commence patient enrollment for its Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection) in Sri Lanka. This follows similar clearance to conduct the Phase III study in the UK and Austria during the past weeks. Further expansion of the trial is underway with a goal to have a total of 880 patients enrolled through about 100 clinical centers in 20 countries by the end of 2015.

CEL-SCI’s global pivotal Phase III clinical trial is the largest trial for head and neck cancer in the world. The trial, which already has over 220 patients enrolled, is assessing the Company’s investigational immunotherapeutic agent Multikine as a potential first-line treatment for advanced primary head and neck cancer. If approved for use following completion of CEL-SCI’s clinical development program for head and neck cancer, Multikine would be a different type of therapy in the fight against cancer; one that appears to have the potential to work with the body’s natural immune system in the fight against tumors.

“If Multikine can be proven to harness the immune system against cancer, we believe this could offer a new modality for the treatment of head and neck cancer that could work in concert with the other methods — surgery, chemotherapy, and radiation therapy, used today for the treatment of this debilitating disease.” stated CEL-SCI Chief Executive Officer Geert Kersten.

About Multikine Phase III Study

The Multikine Phase III study is enrolling patients with advanced primary, not yet treated, head and neck cancer. The objective of the study is to demonstrate a statistically significant improvement in overall survival of enrolled patients who are treated with the Multikine treatment regimen plus Standard of Care (SOC) vs. subjects who are treated with SOC only.

VIENNA, Va.–(BUSINESS WIRE)–

CEL-SCI Corporation (NYSE MKT: CVM) announced today that it has been awarded a Phase I Small Business Innovation Research (SBIR) grant in the amount of $225,000 from the National Institute of Arthritis Muscoskeletal and Skin Diseases (NIAMS), which is part of the National Institutes of Health (NIH). The grant will fund the further development of CEL-SCI’s LEAPS technology as a potential treatment for rheumatoid arthritis (RA), an autoimmune disease of the joints. According to Visiongain, the world rheumatoid arthritis drug market will generate revenues of $38.5 billion in 2017.

The work will be conducted at Rush University Medical Center in Chicago, Illinois in the laboratories of Tibor Glant, MD, Ph.D., The Jorge O. Galante Professor of Orthopedic Surgery; Katalin Mikecz, MD, Ph.D. Professor of Orthopedic Surgery & Biochemistry; and Allison Finnegan, Ph.D. Professor of Medicine.

The NIH grant was awarded based on preliminary data by Dr. Glant’s team in collaboration with CEL-SCI showing that the administration of a proprietary peptide using CEL-SCI’s LEAPS technology prevented the development, and lessened the severity, including inflammation, of experimental RA when it was administered after the disease was induced in the animals. This data was presented in May 2013 by Daniel Zimmerman, Ph.D., CEL-SCI’s Senior Vice President of Research, Cellular Immunology, at the symposium on “Therapeutic Approaches to Autoimmunity” during the American Association of Immunologists (AAI) 100th annual meeting in Honolulu, Hawaii.

“These findings, in conjunction with the results from previously conducted studies with LEAPS vaccines in other RA models suggest that LEAPS vaccines may be used as a therapeutic treatment for different types of RA. LEAPS vaccines may be advantageous to other therapies because the LEAPS vaccines act early on the immune system and inhibit the production of disease-promoting inflammatory cytokines, unlike anti-Tumor necrosis factor alpha (TNFa) therapy which generally acts late and neutralizes only one individual inflammatory cytokine out of many involved in the disease process,” said CEL-SCI’s Dr. Zimmerman.

Dr. Zimmerman continued, “The successful conclusion of this round of studies in this autoimmune disease could take LEAPS closer to human studies and open its development to various other autoimmune diseases, such as multiple sclerosis, uveitis, colitis (Inflammatory Bowel disease) and certain types of diabetes.”

The NIH grant will fund studies in a well-established mouse model for Th1 Proteoglycan induced arthritis (PGIA) as developed by Drs. Glant and Mikecz and recently expanded to a Th17 PGIA by Drs. Finnegan and Glant. These two PGIA models are significant in that they more closely approximate human disease with the concurrent presence of rheumatoid factor and anti citrulline peptide antibodies and spondylitis that are not seen in most arthritis models.

About Rheumatoid Arthritis

Rheumatoid Arthritis is a chronic inflammatory disease that mainly targets the synovial membrane, cartilage and bone. It affects about 1% of the global population and is associated with significant morbidity and increased mortality. Anti-TNF related therapies are the current standard treatment of patients with advanced RA, but over half of the RA patients do not respond to current anti-TNF drugs such as etanercept (Enbrel®) and infliximab (Remicade®).

Nowadays there are millions of apps for smartphone users to choose from but if you live in NYC or even if you’re just visiting there are a few apps that you need to have in your arsenal. These apps promise to make life in NYC a little more convenient and at the very least easier to navigate; so whether you want to get glam, get drunk, or just get around we’ve found an app for that. In this edition of the urban guidebook were going tech.

Top 5 Apps for life in NYC:
-Drizly
-Glamsquad
-SitorSquat
-NYCSampleSales
-Urban Wonderer

Corporate Profile is a content provider for the ClearVISION & ConnectiMED Networks

For more interesting interviews and business profiles please visit our website at www.corporateprofile.com